An interventional study of Primary Palliative Care Complex Intervention (PrimPal) in Palliative Care, Primary Palliative Care and Advanced Cancer, sponsored by University of Coimbra. Recruiting at 2 sites in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University of Coimbra · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Pulmonary Disease, Chronic Obstructive with a site in Portugal — 14 open to participants now, 16 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Portugal.
Among the 54 studies in Pulmonary Disease, Chronic Obstructive with a site in Portugal, this one is the 46th largest by planned enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 with no phase, reaches primary completion later than 10 of the 15 other live ones, and was the 52nd registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 54 studies in Pulmonary Disease, Chronic Obstructive with a site in Portugal are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in Portugal, United States, Denmark and 6 more countries
Ages 18–80
Sanofi · Sites in Portugal, United States, Argentina and 22 more countries
Ages 40–80
University Medical Center Groningen · Sites in Portugal, Czechia, Denmark and 1 more country
Ages 18+
GlaxoSmithKline · Sites in Portugal, United States, Argentina and 20 more countries
Ages 40–80
Instituto Politécnico de Leiria · Sites in Portugal
Ages 40+
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 18 · Phase 4 6
First in 2002; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 258 across the 49 interventional studies, 1,434 across the 5 observational. Of the 35 that completed or were terminated, 16 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 54 have an industry lead sponsor. The 10 most frequent:
University of Coimbra is the lead sponsor of 89 studies on the registry; 27 are open to participants now.
University of Coimbra has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
4 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Portugal that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT06782724University Medical Center GroningenPsilocybin Therapy for Psychological Distress in Palliative Patients | 2027-01-01 |
| NCT07737899University of CoimbraPrimary Palliative Care - a Feasibility Cluster Trial | 2027-02-28 |
| NCT07791147Aveiro UniversityFamily-centred Pulmonary Rehabilitation to Empower Carers | 2027-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Pulmonary Disease, Chronic Obstructive with a site in Portugal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This feasibility cluster-controlled randomized trial (RCT) evaluates a complex intervention for the delivery of primary palliative care in Family Health Units (FHUs). The intervention consists of training General Practitioners (GPs) in palliative care through a 30 hour e-learning program and implementing a structured consultation model (4 consultations over 12 weeks) for adult patients with advanced chronic illness. One FHU will receive the intervention and one FHU will follow usual care. The primary goal is to assess feasibility metrics (GP adherence, patient recruitment rate, and patient retention rate), which will inform the design of a subsequent full-scale cluster RCT.
Background: Demographic ageing and the rising burden of chronic disease have dramatically increased the need for palliative care. Most patients with palliative care needs are cared for in primary health care (PHC) settings, yet GPs often lack training and systematic tools to identify and manage these patients. The Principal Investigator developed a complex intervention combining GP training and a new consultation model during doctoral research, demonstrating promising results (reduction in physical and psychological symptoms) in a before-after study (published in Palliative Medicine, DOI: 10.1177/02692163231219682). The present feasibility trial is the next methodological step before undertaking a full-scale cluster RCT.
Design: Feasibility cluster-controlled RCT with an embedded qualitative component (mixed-methods). Randomisation occurs at the cluster (FHU) level. Two FHUs from ULS Coimbra (central Portugal) will be recruited: one allocated to the intervention arm and one to the control (usual care) arm.
Intervention: GPs in the intervention FHU will complete a 30hour e-learning training programme covering palliative care communication, symptom management, and patient assessment/control. After training, each GP will apply the new structured consultation model to recruited patients over 12 weeks (4 consultations). The model is grounded in the 4th edition of the National Consensus Project's Clinical Practice Guidelines for Quality Palliative Care and WONCA's core competencies for GPs in palliative care.
Control: GPs in the control FHU will follow usual care without any specific palliative care training or structured consultation model.
Participants: Adult patients (≥18 years) on the list of recruited GPs with a diagnosis of: advanced-stage neoplasm (metastatic cancer), COPD GOLD III/IV, Congestive Heart Failure NYHA III/IV, or Chronic Kidney Disease stage IV/V.
Feasibility outcomes: GP implementation rate (primary), patient recruitment rate, and patient retention rate will be assessed at baseline (T0), week 6 (T1), and week 12 (T2). Qualitative data will be collected through interviews with GPs and patients to explore perceived barriers and benefits of the intervention.
Significance: Results will be used to refine the intervention and study procedures, and to power a future definitive cluster RCT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
General Practitioners in the intervention FHU complete a 30hour e-learning training programme in palliative care and apply a new structured consultation model over 12 weeks (4 consultations) with recruited patients.
Other: Primary Palliative Care Complex Intervention (PrimPal)
GPs in the control FHU deliver usual palliative care without specific training or structured consultation model.
1. GPs will receive an e-learning palliative care training programme with a 30-h load, including topics such as the role of communication, the main problems and symptoms of patients with palliative care needs and how to assess and control them. Additionally, the programme covered how to apply the newly developed medical consultation model and how to use the Integrated Palliative Care Outcome Scale (IPOS) patient version 2. Primary palliative care consultation model divided into five areas (1) summarizing clinical information, (2) objective symptoms' management, (3) assessment and coding of chronic diseases and symptoms, (4) planning clinical approach and (5) addressing other problems/concerns - 4 consultations over 12 weeks.
GP Feasibility Rate (Implementation Rate)
Percentage of GPs in the intervention arm who successfully implement the new consultation model with their recruited patients (excluding failures due to reasons unrelated to the physician, e.g., patient death or withdrawal). Feasibility is considered demonstrated if ≥70% of GPs complete the model with at least 80% of their recruited patients.
Time frame: 12 weeks (from start of intervention to end of consultation cycle - Week 12 / T2)
Patient Recruitment Rate
Percentage of contacted eligible patients who agree to participate in the study.
Time frame: Baseline (T0) - during recruitment period
Patient Retention Rate
Percentage of enrolled patients who complete all 4 consultations and remain in the study until week 12.
Time frame: Week 12 (T2)
Perceived Barriers to Implementation
Qualitative exploration of obstacles experienced by GPs and patients in the implementation of the intervention, assessed via semi-structured interviews
Time frame: Week 12 (T2) - end of intervention
Perceived Benefits of the Intervention
Qualitative exploration of the benefits perceived by GPs and patients from the intervention, assessed via semi-structured interviews.
Time frame: Week 12 (T2) - end of intervention
Plan to share: No
Started Oct 2026 (actual). Primary completion is estimated for Feb 2027, 4 months after the start.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 4 months is below that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
University of Coimbra